Brief: Phio Pharmaceuticals Initiates In Vivo Studies Of Intasyl Based Antivirals Against Sars-Cov-2
22/02/2022 14:40
Feb 22 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS INITIATES IN VIVO STUDIES OF INTASYL
BASED
ANTIVIRALS AGAINST SARS-COV-2
Source text for Eikon: ID:nPn2sj3mFa
Further company coverage: PHIO.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing